Sandoz (SDZNY) announced the European launch of its Pyzchiva autoinjector. This is the first ustekinumab biosimilar in Europe commercially available in an autoinjector. Developed and registered by Samsung Bioepis, Pyzchiva is approved for the treatment of adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and pediatric plaque psoriasis for patients aged six years and older, weighing over 60 kg.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SDZNY:
- Sandoz price target lowered to CHF 39 from CHF 41 at Berenberg
- Sandoz upgraded to Outperform from Sector Perform at RBC Capital
- Sandoz announces collaboration license agreement with Henlius
- Sandoz shareholders approve all resolutions at Annual General Meeting
- Sandoz files antitrust litigation against Amgen regarding Enbrel